Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M

Sanara MedTech Inc.

Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.
Net loss $8.1M vs $8.0M in 2021; SG&A expenses rose to $46.0M from $28.1M.
CellerateRX sold in over 700 facilities across 29 states; generated >$5M revenue in a single month.
Entered partnership with InfuSystem for wound care; filed 510(k) for BIASURGE and Precision Healing Imager.
Entered ATM sales agreement with Cantor Fitzgerald for stock offerings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported the quarter and year ended December 31, 2022 results: revenue $45.8 million.

Period: the quarter and year ended December 31, 2022
Revenue: $45.8 million
Result: reported results

Exact text from the filing

for its Precision Healing Multispectral Imager Full Year 2022 Consolidated Financial Results ● Net Revenues. For the year ended December 31, 2022, we generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, a 90% increase from the prior year. Our 2022 net revenues included $6.0 million of Scendia

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008250

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.